Could this ASX healthcare share surge on COVID-19 testing?

Sonic Healthcare Limited (ASX: SHL) shares could surge on the back of a recent contract win from the Australian Government to test for COVID-19.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Testing for the COVID-19 pandemic is an important step in re-opening the Australian economy. The Sonic Healthcare Limited (ASX: SHL) share price could be poised to surge higher in 2020 after the company was recently awarded a contract from the Australian Government to test for COVID-19.  

What contract has Sonic won?

Last week, Sonic Healthcare informed the market that the company had been awarded a contract from the Australian Government to provide rapid sample collection and testing for COVID-19 in residential aged care facilities.

With elderly Australians being the highest priority, approximately 2,700 aged care facilities across the country will be eligible for the service. Sonic will provide testing through its national network of laboratories and collection teams.

Sonic Healthcare's laboratories in New South Wales and Queensland were the first in Australia to perform high-volume COVID-19 testing during the early stages of the pandemic. According to management, Sonic's laboratories have processed almost 20% of all COVID-19 tests in Australia.

Sonic has collectively tested more than 100,000 Australians for COVID-19 and is poised to roll out additional testing platforms across the country.

How has Sonic performed in the pandemic?

Sonic is the third-largest pathology provider in the world, generating revenue from radiology and pathology services. Despite being initially sold down heavily, the Sonic share price has bounced back more than 30% from its low in mid-March.

In late March, Sonic Healthcare informed the market it was withdrawing its earnings guidance for FY20 due to the uncertainty of the CVOID-19 pandemic. The company reached the decision after social isolation and quarantine measures impacted normal diagnostic volumes as patients opted to delay routine testing.

In addition to playing a crucial frontline role, Sonic assured shareholders that the company remained in a strong financial position with a balance sheet boasting almost $1 billion in cash on hand.

Should you buy?

Sonic Healthcare has a history of fuelling growth through acquisitions and winning new contracts. In addition to the contract win from the Australian Government, Sonic has also partnered with philanthropic organisation Minderoo Foundation to increase testing capacity for COVID-19.

If testing proves a successful measure in aged care facilities, the company could be in line for a wider range of contract wins. With the COVID-19 pandemic still an evolving situation, I think Sonic Healthcare's contract win could have great potential in the short and medium-term.

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Sonic Healthcare Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor analysing x-rays.
Healthcare Shares

4DMedical shares are rocketing 11% today. Is a short squeeze starting?

Short sellers may be feeling the heat after this week’s rally.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Shares surge as ASX biotech charts road to redemption

A recent major setback might not be so bad.

Read more »

Young doctor raising arms in air with hands in fists celebrating a new development.
Healthcare Shares

Forget CSL shares, I'd buy this ASX biotech stock instead

Brokers tip this other ASX biotech stock to climb up to 76% higher.

Read more »

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused.
Healthcare Shares

CSL acknowledges "disappointing" results but aims to do better

The search for a new CEO also goes on.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Healthcare Shares

CSL, Resmed, and more. See which ASX health stocks RBC Capital Markets has upgraded

This sector is coming back into favour.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

4DMedical vs Telix Pharmaceuticals: ASX health tech share showdown

4DMedical and Telix are both Aussie health innovators—here’s which ASX share gets my vote in this biotech battle.

Read more »

cochlear happy, share price rise, up, increase
Healthcare Shares

Cochlear share price rebounds 53% from 10-year low: Can it keep climbing?

The shares are still down 47% for the year to date.

Read more »

Donor donates blood in medical clinic. Beautiful European woman of 30 years sits in medical chair looking into camera and smiling.
Healthcare Shares

Two broker upgrades put CSL shares back in focus

CSL is back on the radar after two broker upgrades.

Read more »